Cortexyme jumps after positive safety data on bacterial disorder drug

IRulya Therapeutics

08/03/2022 18:16

** Drug developer's shares  CRTX.O  rise 10.5% to $4.70 in
afternoon trade 
    ** CRTX reports positive results from a part of its
early-stage study testing the safety of its drug candidate,
COR588, in healthy volunteers  urn:newsml:reuters.com:*:nBw8w8pka
    ** Co says early study results indicate the drug was well
tolerated in a certain dose range, with no serious adverse
events
    ** The drug is being developed for the treatment of
disorders related to the P. gingivalis bacteria, including
Alzheimer's
    ** The study's findings also support once daily oral dosing
of drug- co
    ** Expects to report full data from the early-stage trial in
Q2 2022
    ** Including session's gains, stock down 62.8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))